MAKScientific Is Developing Drugs To Treat Disease By Targeting the Endocannabinoid System
Our approach involves the selective targeting of known components of this biochemical system which includes the cannabinoid receptors (CB1 and CB2), a number of enzymes (FAAH, NAAA, DGL, and MGL), and the cannabinoid transporter system. MAKScientific has a large and growing portfolio of small molecule modulators of each target some of which have shown proof-of-concept in selected animal models of human disease. An advanced drug candidate (AM6545) is a peripherally restricted CB1 receptor antagonist that may offer a new way to control chronic liver disease and metabolic disorders.
MAKScientific is developing a pipeline of small molecule modulators that target key intervention points in the endocannabinoid system. A lead pre-clinical drug candidate (AM6545) is a peripherally restricted CB1 receptor neutral antagonist in advanced pre-clinical testing for treating chronic liver disease and metabolic disorders.
MAKScientific is a Boston-based pharmaceutical company focusing on the development of new compounds to treat a variety of diseases modulated by the endocannabinoid system.
MAKScientific is seeking a partner to continue the development and commercialization of its lead CB1 antagonist (AM6545) as a treatment for chronic liver disease and selected metabolic disorders. The drug has already been developed up to the late pre-clinical stage (GMP tox) and has no adverse pre-clinical data to date.